<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539249</url>
  </required_header>
  <id_info>
    <org_study_id>FMCY/O&amp;G/OFAAPPCS/2020</org_study_id>
    <nct_id>NCT04539249</nct_id>
  </id_info>
  <brief_title>Opioid-free Analgesia for the Management of Acute Post-operative Pain Following Caesarean Section</brief_title>
  <acronym>OFAAPPCS</acronym>
  <official_title>Use of Opioid-free Analgesia for the Management of Acute Post-operative Pain Following Caesarean Section: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olakunle Ifeoluwa Makinde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Medical Centre, Yenagoa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Multimodal analgesia; a combination of opioid and non-opioid analgesics, for&#xD;
      management of acute post-operative pain significantly reduces the incidence of adverse&#xD;
      effects associated with liberal post-operative opioid use including sedation, respiratory&#xD;
      depression, constipation, ileus, urinary retention, delayed recovery, addiction etc. However,&#xD;
      opioid addiction remains a worsening public health problem and have followed administration&#xD;
      of opioid analgesics for post-operative pain and subsequent chronic use in many addicts;&#xD;
      especially the opioid naive. Caesarean section is a commonly performed surgery and is a&#xD;
      common source of first exposure to opioids in women. Trend in post-operative analgesia is&#xD;
      moving towards opioid-free (multimodal) analgesia; a combination of non-opioid and adjuvant&#xD;
      analgesics. Magnesium sulphate is an adjuvant analgesic. When administered peri-operatively,&#xD;
      it has been reported to prolong the duration of spinal anaesthesia, decrease post-operative&#xD;
      pain and opioid use without adverse effect.&#xD;
&#xD;
      Aim: To determine the effectiveness of a combination of intravenous magnesium sulphate,&#xD;
      intravenous paracetamol, and rectal diclofenac as opioid-free analgesia for management of&#xD;
      acute post-operative pain after a caesarean section.&#xD;
&#xD;
      Null Hypothesis: Combination of intravenous magnesium sulphate, intravenous paracetamol, and&#xD;
      rectal diclofenac as analgesic regimen for acute post-operative pain after a caesarean&#xD;
      section is not as effective as the standard opioid-based multimodal analgesia regimen used at&#xD;
      Federal Medical Centre, Yenagoa.&#xD;
&#xD;
      Alternate Hypothesis: Combination of intravenous magnesium sulphate, intravenous paracetamol,&#xD;
      and rectal diclofenac as analgesic regimen for acute post-operative pain after a caesarean&#xD;
      section is as effective as the standard opioid-based multimodal analgesia regimen used at&#xD;
      Federal Medical Centre, Yenagoa.&#xD;
&#xD;
      Materials and Methods: A randomized clinical trial, comparing a combination of intravenous&#xD;
      magnesium sulphate, intravenous paracetamol, and rectal diclofenac with an opioid-based&#xD;
      multimodal regimen as control. Eligible patients will be consecutively selected from among&#xD;
      women booked for caesarean section at the Federal Medical Centre, Yenagoa. Control group will&#xD;
      receive a combination of intramuscular pentazocine, intravenous paracetamol and rectal&#xD;
      diclofenac. Pain intensity will be determined in both groups and compared. Need for rescue&#xD;
      opioid in the opioid-free analgesia treated patients and incidence of any adverse event in&#xD;
      both groups will be determined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative pain scores following caesarean section at 4 hours post-operative</measure>
    <time_frame>4 hours post-operative</time_frame>
    <description>Numerical Rating Scale pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative pain scores following caesarean section at 8 hours post-operative</measure>
    <time_frame>8 hours post-operative</time_frame>
    <description>Numerical Rating Scale pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative pain scores following caesarean section at 24 hours post-operative</measure>
    <time_frame>24 hours post-operative</time_frame>
    <description>Numerical Rating Scale pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative pentazocine use and dose used</measure>
    <time_frame>First 24 hours post-operative</time_frame>
    <description>Milligrams of pentazocine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of preoperative, intraoperative and post-operative adverse events</measure>
    <time_frame>First 48 hours post-operative</time_frame>
    <description>Hypersensitivity reaction, hypotension, respiratory depression, bradycardia, nausea and vomiting, constipation, ileus, pruritus, urinary retention, uterine atony and any other adverse event recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Acute Post-operative Pain Following Caesarean Section</condition>
  <arm_group>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of intravenous magnesium sulphate, intravenous paracetamol and rectal diclofenac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentazocine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of intramuscular pentazocine, intravenous paracetamol and rectal diclofenac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate</intervention_name>
    <description>1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.&#xD;
N.B: Intramuscular pentazocine 30 mg (45 mg if patient is &gt; 70 kg) will be used only as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite non-opioid analgesia) at least 4 hourly during the first 24 hours after caesarean section.</description>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <other_name>MgSO4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentazocine</intervention_name>
    <description>Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is &gt; 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.</description>
    <arm_group_label>Pentazocine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women booked for caesarean section at the Federal Medical Centre, Yenagoa who&#xD;
             gives consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with active peptic ulcer disease, active liver disease, hepatic&#xD;
             failure, and renal failure,&#xD;
&#xD;
          -  Pregnant women with previous history of ischaemic heart disease/myocardial infarction,&#xD;
             heart failure, venous thrombosis and stroke,&#xD;
&#xD;
          -  Hypersensitivity to pentazocine, paracetamol, diclofenac or magnesium sulphate,&#xD;
&#xD;
          -  Pregnant women with history of non-medical use (abuse) of opioids,&#xD;
&#xD;
          -  Pregnant women on magnesium sulphate or have a clinical indication to receive&#xD;
             magnesium sulphate,&#xD;
&#xD;
          -  Pregnant women booked for emergency caesarean section (because the urgency may not&#xD;
             allow time for adequate patient counseling before recruitment)&#xD;
&#xD;
          -  Pregnant women booked for caesarean section under general anaesthesia or epidural&#xD;
             anaesthesia,&#xD;
&#xD;
          -  Pregnant women who decline to participate in the study,&#xD;
&#xD;
          -  Pregnant women who can neither communicate in english nor colloquial english.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olakunle I Makinde, MBChB, MWACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal Medical Centre, Yenagoa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal Medical Centre, Yenagoa</name>
      <address>
        <city>Yenagoa</city>
        <state>Bayelsa State</state>
        <zip>560231</zip>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <reference>
    <citation>Vadivelu N, Mitra S, Schermer E, Kodumudi V, Kaye AD, Urman RD. Preventive analgesia for postoperative pain control: a broader concept. Local Reg Anesth. 2014 May 29;7:17-22. doi: 10.2147/LRA.S62160. eCollection 2014. Review.</citation>
    <PMID>24872720</PMID>
  </reference>
  <reference>
    <citation>Kim M. An opioid success story: efforts to minimize painkillers after surgery appear to be working. Johannesburg, South Africa: The Conversation Africa, Inc.; 2019.</citation>
  </reference>
  <reference>
    <citation>Johnson SR. Hospitals look to cut opioids from surgery and beyond. Detroit, Michigan: Crain communications, Inc.; 2019.</citation>
  </reference>
  <reference>
    <citation>Dinis J, Soto E, Pedroza C, Chauhan SP, Blackwell S, Sibai B. Nonopioid versus opioid analgesia after hospital discharge following cesarean delivery: a randomized equivalence trial. Am J Obstet Gynecol. 2020 May;222(5):488.e1-488.e8. doi: 10.1016/j.ajog.2019.12.001. Epub 2019 Dec 6.</citation>
    <PMID>31816306</PMID>
  </reference>
  <reference>
    <citation>Kahraman F, Eroglu A. The effect of intravenous magnesium sulfate infusion on sensory spinal block and postoperative pain score in abdominal hysterectomy. Biomed Res Int. 2014;2014:236024. doi: 10.1155/2014/236024. Epub 2014 Mar 19.</citation>
    <PMID>24772415</PMID>
  </reference>
  <reference>
    <citation>McKeown A, Seppi V, Hodgson R. Intravenous Magnesium Sulphate for Analgesia after Caesarean Section: A Systematic Review. Anesthesiol Res Pract. 2017;2017:9186374. doi: 10.1155/2017/9186374. Epub 2017 Dec 3. Review.</citation>
    <PMID>29333156</PMID>
  </reference>
  <reference>
    <citation>Shin HJ, Kim EY, Na HS, Kim TK, Kim MH, Do SH. Magnesium sulphate attenuates acute postoperative pain and increased pain intensity after surgical injury in staged bilateral total knee arthroplasty: a randomized, double-blinded, placebo-controlled trial. Br J Anaesth. 2016 Oct;117(4):497-503. doi: 10.1093/bja/aew227. Epub 2016 Oct 17.</citation>
    <PMID>28077538</PMID>
  </reference>
  <reference>
    <citation>Kalani N, Sanie MS, Zabetian H, Radmehr M, Sahraei R, Kargar Jahromi H, Zare Marzouni H. Comparison of the Analgesic Effect of Paracetamol and Magnesium Sulfate during Surgeries. World J Plast Surg. 2016 Sep;5(3):280-286.</citation>
    <PMID>27853692</PMID>
  </reference>
  <reference>
    <citation>Murphy JD, Paskaradevan J, Eisler LL, Ouanes JP, Tomas VA, Freck EA, Wu CL. Analgesic efficacy of continuous intravenous magnesium infusion as an adjuvant to morphine for postoperative analgesia: a systematic review and meta-analysis. Middle East J Anaesthesiol. 2013 Feb;22(1):11-20. Review.</citation>
    <PMID>23833845</PMID>
  </reference>
  <reference>
    <citation>Albrecht E, Kirkham KR, Liu SS, Brull R. Peri-operative intravenous administration of magnesium sulphate and postoperative pain: a meta-analysis. Anaesthesia. 2013 Jan;68(1):79-90. doi: 10.1111/j.1365-2044.2012.07335.x. Epub 2012 Nov 1. Review.</citation>
    <PMID>23121612</PMID>
  </reference>
  <reference>
    <citation>Hwang JY, Na HS, Jeon YT, Ro YJ, Kim CS, Do SH. I.V. infusion of magnesium sulphate during spinal anaesthesia improves postoperative analgesia. Br J Anaesth. 2010 Jan;104(1):89-93. doi: 10.1093/bja/aep334.</citation>
    <PMID>19933175</PMID>
  </reference>
  <reference>
    <citation>Apan A, Buyukkocak U, Ozcan S, Sari E, Basar H. Postoperative magnesium sulphate infusion reduces analgesic requirements in spinal anaesthesia. Eur J Anaesthesiol. 2004 Oct;21(10):766-9.</citation>
    <PMID>15678729</PMID>
  </reference>
  <reference>
    <citation>Helmy N, Badawy AA, Hussein M, Reda H. Comparison of the preemptive analgesia of low dose ketamine versus magnesium sulphate on parturient undergoing caesarean section under general anaesthesia. Egypt. J. Anaesth. 2015;31(1):53-58.</citation>
  </reference>
  <reference>
    <citation>Paech MJ, Magann EF, Doherty DA, Verity LJ, Newnham JP. Does magnesium sulfate reduce the short- and long-term requirements for pain relief after caesarean delivery? A double-blind placebo-controlled trial. Am J Obstet Gynecol. 2006 Jun;194(6):1596-602; discussion 1602-3. Epub 2006 Apr 17.</citation>
    <PMID>16615926</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Federal Medical Centre, Yenagoa</investigator_affiliation>
    <investigator_full_name>Olakunle Ifeoluwa Makinde</investigator_full_name>
    <investigator_title>Senior Registrar</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Pentazocine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Participant Data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Starting 3 months after publication</ipd_time_frame>
    <ipd_access_criteria>Open access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

